Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Kupando

Ownership
Private
Employees
~10
Therapeutic Areas
OncologyInfectious Diseases
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small moleculesTLR 4/7 agonists

Kupando General Information

Developing KUP101, the only TLR 4/7 agonist in development, consisting of two small molecules co-encapsulated. Currently in IND-enabling work for treatment of solid tumors and prophylaxis of infectious diseases

Contact Information

Website
https://www.kupando.com/
Primary Industry
Biotech
Corporate Office
Schönefeld, Brandenburg
Germany

Drug Pipeline

KUP101
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Kupando's pipeline data

Book a demo

Key Partnerships

Strategic partnerships mentioned but specific partners not named

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Kupando Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Kupando's complete valuation and funding history, request access »

Kupando Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals